Skip to content

SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases

SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases From Non-small Cell Lung Cancer, an Open, Randomized Phase II Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05577052
Enrollment
100
Registered
2022-10-13
Start date
2022-10-30
Completion date
2024-12-30
Last updated
2022-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Keywords

SBRT, NSCLC, Vertebral metastasis

Brief summary

Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture. For vertebral metastases who are not yet at risk of vertebral instability fracture, a moderate dose (30Gy/10F) external radiation therapy is the most widely used treatment technique. Previous studies have shown that 60-80% of patients could achieve pain relief with moderate doses of radiation therapy, with median pain control duration of approximately 4 months. Stereotactic Radiation Therapy (SBRT) is currently the most advanced radiation therapy technique. This project proposes to treat vertebral metastases from non-small cell lung cancer using SBRT technology on the True Beam radiotherapy system to compare its efficacy with conventional external irradiation technology in terms of pain relief as well as local control.

Detailed description

Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture. For vertebral metastases who are not yet at risk of vertebral instability fracture, a moderate dose (30Gy/10F) external radiation therapy is the most widely used treatment technique. Previous studies have shown that 60-80% of patients could achieve pain relief with moderate doses of radiation therapy, with median pain control duration of approximately 4 months. Stereotactic Radiation Therapy (SBRT) is currently the most advanced radiation therapy technique. It enables focused radiation therapy with small fields through stereotactic techniques. In June 2021, Zhongnan Hospital of Wuhan University introduced the True Beam radiotherapy system, which has a higher treatment rate compared to conventional radiotherapy equipment, while It is the most reliable vehicle to achieve SBRT. Therefore, this project proposes to treat vertebral metastases from non-small cell lung cancer using SBRT technology on the True Beam radiotherapy system to compare its efficacy with conventional external irradiation technology in terms of pain relief as well as local control.

Interventions

RADIATIONMetastatic vertebrae treated with SBRT

High-dose SBRT treatment

Sponsors

Wuhan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Pathologically confirmed stage IV non-small cell lung cancer. * General condition score ≤ 2. * With vertebral metastases combined with painful symptoms. * Absence of neurological symptoms due to vertebral metastases, such as dyskinesia, defecation or urination abnormalities. * No previous radiation treatment of any kind to the vertebral body. * The metastatic vertebra has not been treated surgically * Vertebral stability score (SINS) ≤ 12 * Patient life expectancy of more than 6 months.

Exclusion criteria

* Small cell cell lung cancer or large cell carcinoma * General condition score \>2, intolerant of radiotherapy. * Comorbid neurological symptoms such as dyskinesia, abnormal bowel movements or urination * Metastatic vertebrae that have received radiotherapy or surgical intervention * Vertebral stability score (SINS) \>12 * Patient life expectancy of less than 6 months

Design outcomes

Primary

MeasureTime frameDescription
Complete pain relief rate3 monthsComplete pain relief rate after completion of radiotherapy

Secondary

MeasureTime frameDescription
Quality of life scores3 months and 6 monthsQuality of life score after radiotherapy

Contacts

Primary ContactJing Yu, Dr
yujingrt@163.com02767812539

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026